Clough Capital Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$878K Hold
6,300
0.08% 91
2025
Q4
$773K Hold
6,300
0.07% 107
2025
Q3
$699K Hold
6,300
0.06% 104
2025
Q2
$698K Hold
6,300
0.07% 95
2025
Q1
$706K Hold
6,300
0.09% 86
2024
Q4
$582K Hold
6,300
0.07% 99
2024
Q3
$528K Hold
6,300
0.05% 117
2024
Q2
$432K Hold
6,300
0.05% 108
2024
Q1
$461K Hold
6,300
0.05% 111
2023
Q4
$510K Sell
6,300
-1,400
-18% -$109K 0.06% 136
2023
Q3
$577K Hold
7,700
0.06% 126
2023
Q2
$593K Hold
7,700
0.06% 145
2023
Q1
$639K Hold
7,700
0.07% 140
2022
Q4
$661K Buy
+7,700
New +$610K 0.07% 138
2020
Q3
Sell
-103,200
Closed -$7.94M 131
2020
Q2
$7.94M Sell
103,200
-83,800
-45% -$6.42M 0.78% 50
2020
Q1
$14M Buy
+187,000
New +$12.9M 1.39% 23
2017
Q1
Sell
-248,322
Closed -$17.8M 162
2016
Q4
$17.8M Buy
248,322
+118,822
+92% +$8.83M 1.18% 29
2016
Q3
$10.2M Buy
129,500
+61,900
+92% +$5.03M 0.53% 64
2016
Q2
$5.64M Buy
+67,600
New +$6M 0.3% 101
2015
Q3
Sell
-114,316
Closed -$13.4M 209
2015
Q2
$13.4M Sell
114,316
-77,140
-40% -$8.43M 0.51% 73
2015
Q1
$18.8M Buy
+191,456
New +$19.4M 0.62% 70
2014
Q2
Sell
-283,046
Closed -$20.1M 206
2014
Q1
$20.1M Sell
283,046
-39,200
-12% -$3.07M 0.63% 61
2013
Q4
$24.2M Sell
322,246
-9,600
-3% -$668K 0.8% 45
2013
Q3
$20.9M Buy
331,846
+8,000
+2% +$478K 0.65% 59
2013
Q2
$16.6M Buy
+323,846
New +$16.9M 0.55% 65

Other funds holding GILD

Clough Capital Partners's GILD Position: Q1 2026 in Review

Clough Capital Partners held its Gilead Sciences (GILD) position steady in Q1 2026 at 6,300 shares worth $878K. The position accounts for 0.08% of the portfolio, ranked #91.

Clough Capital Partners first reported a position in GILD in Q2 2013 and has held it in 25 quarters since. The position peaked at $24.2M in Q4 2013. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Clough Capital Partners held 6,300 shares of Gilead Sciences worth $878K as of Q1 2026.
  • Clough Capital Partners left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.08% of Clough Capital Partners's portfolio in Q1 2026, its #91 holding.
  • Clough Capital Partners first reported a position in Gilead Sciences in Q2 2013 and has held it in 25 quarters since.
  • Clough Capital Partners's Gilead Sciences position peaked at $24.2M in Q4 2013.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Clough Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.